Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy

Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy

Purpose: To test and internally validate serum Pentraxin-3 (PTX3) levels as a potential PCa biomarker to predict prostate biopsy (PBx) results. Materials and Methods: Serum PSA and serum PTX3 were prospectively assessed in patients scheduled for PBx at our Institution due to increased serum PSA leve...

Full description

Bibliographic Details
Main Authors: Ugo Giovanni Falagario, Gian Maria Busetto, Giuseppe Stefano Netti, Francesca Sanguedolce, Oscar Selvaggio, Barbara Infante, Elena Ranieri, Giovanni Stallone, Giuseppe Carrieri, Luigi Cormio
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
prostate cancer
prostate biopsy
biomarkers
decision curve analysis
pentraxin 3
Online Access:https://www.mdpi.com/2072-6694/13/7/1611

Similar Items

Similar Items